GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Financials Guangzhou Kingmed Diagnostics Group Co., Ltd.
Equities
603882
CNE100002VW1
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.35 CNY | -4.84% |
|
-14.49% | -38.71% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 23,453 | 58,870 | 51,852 | 36,530 | 29,331 | 17,825 | - | - |
| Enterprise Value (EV) 1 | 23,453 | 57,696 | 49,649 | 33,966 | 27,272 | 11,622 | 12,088 | 13,834 |
| P/E ratio | 58.2 x | 39.2 x | 23.4 x | 13.3 x | 45.3 x | 14.3 x | 12.5 x | 16.9 x |
| Yield | 0.27% | 0.26% | 1.15% | 2.28% | 1.41% | 2.32% | 2.96% | 0.63% |
| Capitalization / Revenue | 4.45 x | 7.14 x | 4.34 x | 2.36 x | 3.43 x | 1.78 x | 1.51 x | 1.47 x |
| EV / Revenue | 4.45 x | 7 x | 4.16 x | 2.19 x | 3.19 x | 1.16 x | 1.02 x | 1.14 x |
| EV / EBITDA | 29.5 x | 26.6 x | 15 x | 8.82 x | 20.7 x | 6.24 x | 5.37 x | 7.46 x |
| EV / FCF | - | - | - | - | 51 x | 18.7 x | 7.68 x | - |
| FCF Yield | - | - | - | - | 1.96% | 5.36% | 13% | - |
| Price to Book | 10.3 x | 15.5 x | 8.23 x | 4.23 x | 3.51 x | 2.04 x | 1.62 x | - |
| Nbr of stocks (in thousands) | 457,885 | 459,488 | 465,586 | 467,139 | 468,771 | 464,791 | - | - |
| Reference price 2 | 51.22 | 128.1 | 111.4 | 78.20 | 62.57 | 38.35 | 38.35 | 38.35 |
| Announcement Date | 4/28/20 | 4/19/21 | 4/26/22 | 4/24/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,269 | 8,244 | 11,943 | 15,476 | 8,540 | 10,003 | 11,818 | 12,144 |
| EBITDA 1 | 793.9 | 2,166 | 3,311 | 3,851 | 1,319 | 1,862 | 2,253 | 1,854 |
| EBIT 1 | 484 | 1,817 | 2,777 | 3,347 | 759.8 | 1,446 | 1,745 | 1,213 |
| Operating Margin | 9.19% | 22.04% | 23.25% | 21.63% | 8.9% | 14.46% | 14.76% | 9.99% |
| Earnings before Tax (EBT) 1 | 495.7 | 1,810 | 2,748 | 3,321 | 740.3 | 1,450 | 1,663 | 1,266 |
| Net income 1 | 402.3 | 1,510 | 2,220 | 2,753 | 643.4 | 1,142 | 1,392 | 1,054 |
| Net margin | 7.64% | 18.31% | 18.58% | 17.79% | 7.53% | 11.42% | 11.78% | 8.68% |
| EPS 2 | 0.8800 | 3.270 | 4.760 | 5.890 | 1.380 | 2.673 | 3.073 | 2.266 |
| Free Cash Flow 1 | - | - | - | - | 535 | 623 | 1,573 | - |
| FCF margin | - | - | - | - | 6.27% | 6.23% | 13.31% | - |
| FCF Conversion (EBITDA) | - | - | - | - | 40.56% | 33.46% | 69.82% | - |
| FCF Conversion (Net income) | - | - | - | - | 83.16% | 54.55% | 112.97% | - |
| Dividend per Share 2 | 0.1360 | 0.3290 | 1.280 | 1.780 | 0.8800 | 0.8882 | 1.133 | 0.2400 |
| Announcement Date | 4/28/20 | 4/19/21 | 4/26/22 | 4/24/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,326 | 4,251 | 4,061 | 3,895 | 3,268 | 2,118 | 2,191 | 2,001 | 2,230 | 1,841 | 2,113 | 2,229 | 2,229 | 2,149 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 734 | 1,075 | 978 | 946 | 348.2 | 164.4 | 334.4 | 306.1 | 117.3 | -25.02 | 270.8 | 232.4 | 272 | 275.6 |
| Operating Margin | 22.07% | 25.29% | 24.08% | 24.28% | 10.65% | 7.77% | 15.26% | 15.3% | 5.26% | -1.36% | 12.82% | 10.43% | 12.2% | 12.83% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | -18.64 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | -1.01% | - | - | - | - |
| EPS 2 | 1.190 | 1.820 | 1.690 | 1.730 | 0.6500 | 0.3200 | 0.2900 | 0.6200 | 0.1500 | -0.0400 | 0.3500 | - | 0.4400 | 0.5000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/26/22 | 4/26/22 | 8/17/22 | 10/27/22 | 4/24/23 | 4/24/23 | 8/28/23 | 10/27/23 | 4/25/24 | 4/25/24 | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,174 | 2,204 | 2,564 | 2,059 | 6,203 | 5,736 | 3,991 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 535 | 623 | 1,573 | - |
| ROE (net income / shareholders' equity) | 19.2% | 50.1% | 44.2% | 37% | 7.54% | 10.1% | 13.7% | 11.3% |
| ROA (Net income/ Total Assets) | 9.63% | 27.4% | 25.5% | 22.3% | - | 6.7% | 8.8% | 7.8% |
| Assets 1 | 4,177 | 5,517 | 8,695 | 12,321 | - | 17,047 | 15,822 | 13,509 |
| Book Value Per Share 2 | 4.970 | 8.240 | 13.50 | 18.50 | 17.80 | 18.80 | 23.70 | - |
| Cash Flow per Share 2 | 1.440 | 3.310 | 4.480 | 4.170 | 2.630 | 3.280 | 3.400 | - |
| Capex 1 | 271 | 540 | 952 | 820 | 696 | 647 | 634 | - |
| Capex / Sales | 5.13% | 6.55% | 7.97% | 5.3% | 8.15% | 6.47% | 5.36% | - |
| Announcement Date | 4/28/20 | 4/19/21 | 4/26/22 | 4/24/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
38.35
CNY
Average target price
71.03
CNY
Spread / Average Target
+85.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.71% | 2.46B | |
| -19.14% | 8.22B | |
| +45.10% | 3.73B | |
| -7.18% | 2.46B | |
| -8.50% | 2.36B | |
| -13.72% | 1.78B | |
| -19.73% | 1.52B | |
| -40.78% | 1.21B | |
| +8.32% | 1.12B | |
| -11.81% | 1.09B |
- Stock Market
- Equities
- 603882 Stock
- Financials Guangzhou Kingmed Diagnostics Group Co., Ltd.
